154590-66-6

Basic information

• Product Name: (S)-N-((3-(3-Fluoro-4-piperazin-1-ylphenyl)-2-oxooxazolidin-5-yl)Methyl)-acetaMide
• Synonyms: (S)-N-((3-(3-Fluoro-4-piperazin-1-ylphenyl)-2-oxooxazolidin-5-yl)Methyl)-acetaMide;Acetamide,N-[[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-
• CAS NO: 154590-66-6
• Molecular Formula: C₁₆H₂₁FN₄O₃
• Molecular Weight: 336.3613432
• EINECS: -0
• Mol File: 154590-66-6.mol

Chemical Properties

• Boiling Point: 587.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.273±0.06 g/cm3(Predicted)
• PKA: 15.53±0.46(Predicted)
• CAS DataBase Reference: (S)-N-((3-(3-Fluoro-4-piperazin-1-ylphenyl)-2-oxooxazolidin-5-yl)Methyl)-acetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-((3-(3-Fluoro-4-piperazin-1-ylphenyl)-2-oxooxazolidin-5-yl)Methyl)-acetaMide(154590-66-6)
• EPA Substance Registry System: (S)-N-((3-(3-Fluoro-4-piperazin-1-ylphenyl)-2-oxooxazolidin-5-yl)Methyl)-acetaMide(154590-66-6)

Safety Data

• Hazardous Substances Data: 154590-66-6(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
L-Alanosine is used as an antitumor agent for its potential therapeutic effects against various types of cancer. Its mechanism of action involves inhibiting adenosine kinase, a key enzyme in the synthesis of DNA and RNA in cancer cells, thereby disrupting nucleic acid synthesis and leading to the death of cancer cells.
Used in Solid Tumor Treatment:
L-Alanosine is being studied for its potential in treating solid tumors due to its ability to target and inhibit adenosine kinase, a critical enzyme in the nucleic acid synthesis of cancer cells.
Used in Hematological Malignancy Treatment:
L-Alanosine is also being investigated for its therapeutic potential in the treatment of hematological malignancies, as it can effectively inhibit adenosine kinase, a key enzyme involved in the synthesis of DNA and RNA in cancer cells, leading to the disruption of nucleic acid synthesis and the death of cancer cells.

Upstream product

• 174649-06-0 (S)-N-[[3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 
• 212694-67-2 3-fluoro-4-(piperazin-1-yl)benzenamine 
• 174649-05-9 (S)-N-[[3-[3-fluoro-4-[4-carbobenzoxypiperazin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide 
• 239438-48-3 (R)-[N-3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methyl azide 
• 1281885-30-0 (R)-benzyl 4-(2-fluoro-4-(2-oxo-5-(tosyloxymethyl)oxazolidin-3-yl)phenyl)piperazine-1-carboxylate 
• 1281885-22-0 3-fluoro-4-piperazin-1-yl-phenylamine dihydrochloride 
• 174649-03-7 N-carbobenzoxy-3-fluoro-4-(N-carbobenzoxypiperazin-1-yl)aniline 
• 174649-04-8 (R)-[N-3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methanol 
• 198410-25-2 (S)-N-(3-(3-fluoro-4-((N-4-carbobenzoxy)piperazin-1-yl)phenyl)-2-oxo-oxazolidin-5-yl)methylamine 
• 183905-31-9 N-[(2S)-2-acetoxy-3-chloropropyl]acetamide 
• 183805-10-9 N-[(2S)oxiranylmethyl]acetamide 
• 154590-33-7 1-(2-fluoro-4-nitrophenyl)piperazine 
• 154590-62-2 (R)-tert-butyl-4-(2-fluoro-4-(5-(hydroxymethyl)-2-oxooxazolidin-3-yl)phenyl)piperazine-1-carboxylate 
• 154590-34-8 4-(2-fluoro-4-nitrophenyl)-piperazine-1-carboxylic acid tert butyl ester 

Downstream Products

• 595582-84-6 N-(3-{3-fluoro-4-[4-(2-nitro-benzenesulfonyl)-piperazin-1-yl]-phenyl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide 
• 444335-12-0 7-(4-{4-[(S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl}-piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 510728-78-6 9-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl}-piperazin-1-yl)-8-fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1-oxa-3,3a-diaza-phenalene-5-carboxylic acid ethyl ester 

Relevant articles and documents

Oxazolidinone compound containing piperazine hydrazone structure

The invention discloses an oxazolidinone compound containing a piperazine hydrazone structure. The oxazolidinone compound comprises a compound shown as a general formula (I), or stereisomer thereof, or pharmaceutically-acceptable salt thereof, or solvate thereof or prodrug thereof, wherein R1 is hydrogen, fluorine, chlorine or trifluoromethyl, R2 is -NHCOCH3 or -OH, R3 is Ar which is C5-C10 aryl substituted by any 1-3 R4 and heteroaryl, and R4 is hydrogen, hydroxyl, halogen, nitro, amino, cyan, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl substituted by hydroxyl, amino or halogen, C1-C6 alkoxy substituted by hydroxyl, amino or halogen, amino substituted by mono- or bi-(C1-C6 alkyl), C1-C6 alkyl amido, free, salty, esterified and amidated hydroxyl, C1-C6 alkyl sulfinyl, C1-C6 alkyl sulfonyl, C1-C6 alkyl acyl and carbamoyl. The oxazolidinone compound can be used for preparing drug for treating microbial infection.

Synthesis of conjugates between oxazolidinone antibiotics and a pyochelin analogue

Pseudomonas aeruginosa is a Gram-negative pathogenic bacterium responsible for severe infections, and it is naturally resistant to many clinically approved antibiotic families. Oxazolidinone antibiotics are active against many Gram-positive bacteria, but

An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants

An azide-functionalised analogue of the oxazolidinone antibiotic linezolid was synthesised and shown to retain antimicrobial activity. Using facile 'click' chemistry, this versatile intermediate can be further functionalised to explore antimicrobial structure-activity relationships or conjugated to fluorophores to generate fluorescent probes. Such probes can report bacteria and their location in a sample in real time. Modelling of the structures bound to the cognate 50S ribosome target demonstrates binding to the same site as linezolid is possible. The fluorescent probes were successfully used to image Gram-positive bacteria using confocal microscopy.

Discovery of a novel nitroimidazolyl-oxazolidinone hybrid with potent anti Gram-positive activity: Synthesis and antibacterial evaluation

A number of linezolid analogues containing a nitroaryl-1,3,4-thiadiazole moiety, were prepared and evaluated as antibacterial agents against a panel of Gram-positive and Gram-negative bacteria. Among synthesized compounds, nitrofuran analogue 1b exhibited more potent inhibitory activity, with respect to other synthesized compounds and reference drug linezolid. The target compounds were also assessed for their cytotoxic activity against normal mouse fibroblast (NIH/3T3) cells using MTT assay. The results indicated that compound 1c exhibit potent antibacterial activity against Gram-positive bacteria at non-cytotoxic concentrations.

Anti-tubercular agents. Part 6: Synthesis and antimycobacterial activity of novel arylsulfonamido conjugated oxazolidinones

As a part of investigation of new anti-tubercular agents in this laboratory, herein we describe the synthesis of a new class of arylsulfonamido conjugated oxazolidinones. The in vitro activity of these conjugated (6a-f, 7a-d, 9a-c and 11a-c) molecules aga

BORON CONTAINING SMALL MOLECULES

This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Synthesis and antibacterial activities of eperezolid analogs with glycinyl substitutions

A series of eperezolid analogs with glycinyl substitutions were prepared and their antibacterial activities were studied against a panel of susceptible and resistant Gram-positive bacteria. The compounds with N-arylacyl or N-heteroarylacyl glycinyl struct

Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents

Novel oxazolidinone antibacterials bearing a variety of 3-indolylglyoxamide substituents have been explored in an effort to improve the spectrum and potency of this class of agents. A subclass of this series was also made with the diversity at C-5 terminus. These derivatives have been screened against a panel of clinically relevant Gram-positive pathogens and fastidious Gram-negative organisms. Several analogs in this series were identified with in vitro activity superior to linezolid (MIC = 0.25-2 μg/mL). Compounds 10a, 10c, 10e and 10f displayed activity against linezolid resistant Gram-positive organisms (MIC = 2-4 μg/mL). Selected oxazolidinones were evaluated for in vivo efficacy against a mouse systemic infection model.

Synthesis and evaluation of urea and thiourea derivatives of oxazolidinones as antibacterial agents

Urea and thiourea derivatives of oxazolidinones were synthesized and their inhibitory activity (MIC) was determined on the bacterial strains which includes clinical isolates and quality control organisms. The structure activity relationships were studied

Short and practical enantioselective synthesis of linezolid and eperezolid via proline-catalyzed asymmetric α-aminooxylation

An efficient enantioselective synthesis of the antibacterials, linezolid (U-100766), and eperezolid (U-100592) using d-proline-catalyzed asymmetric α-aminooxylation of aldehydes as the key step is described here. This is the first report on the enantioselective synthesis of linezolid and eperezolid using asymmetric catalysis.